Oral Mucositis
, Ahmad Ameri1 and Mona Malekzadeh2 (1) Department of Clinical Oncology, Imam Hossein Educational Hospital, Shahid Beheshti University of Medical Sciences (SBMU), Shahid Madani Street, Tehran, Iran (2) Department of Radiotherapy and…
ONCOLOGY
Radiation Orbital Toxicity
, Ahmad Ameri1 and Mona Malekzadeh2 (1) Department of Clinical Oncology, Imam Hossein Educational Hospital, Shahid Beheshti University of Medical Sciences (SBMU), Shahid Madani Street, Tehran, Iran (2) Department of Radiotherapy and…
Ear Toxicity
, Ahmad Ameri1 and Mona Malekzadeh2 (1) Department of Clinical Oncology, Imam Hossein Educational Hospital, Shahid Beheshti University of Medical Sciences (SBMU), Shahid Madani Street, Tehran, Iran (2) Department of Radiotherapy and…
Radiation Brain Injury
, Ahmad Ameri1 and Mona Malekzadeh2 (1) Department of Clinical Oncology, Imam Hossein Educational Hospital, Shahid Beheshti University of Medical Sciences (SBMU), Shahid Madani Street, Tehran, Iran (2) Department of Radiotherapy and…
The Role of PET/CT in Prostate Cancer Management
Fig. 5.1 A normal 18F-choline PET scan (MIP image). Physiological uptake of choline is present in the salivary glands, liver, spleen, kidneys, bowel and bladder with low-grade normal bone marrow…
Epidemiology and Clinical Features
Fig. 1.1 Estimated age-standardised rates (World) per 100,000 [2] Fig. 1.2 Trends in incidence of prostate cancer in selected countries: age-standardised rate (W) per 100,000 [2] Fig. 1.3 The 20…
Pathology of Prostate Cancer
Fig. 2.1 Immunohistochemistry demonstrates basal cells (stained brown with marker 34betaE12) in benign glands, while the surrounding malignant glands are negative 2.3 Immunohistochemistry The immunostains commonly used are p63 (nuclear…
Role of Radiolabelled Small Molecules Binding to PSMA in Diagnosis and Therapy of Prostate Cancer
Fig. 6.1 After ligand binding to PSMA the ligand-PSMA complex is internalized, resulting in an effective accumulation of the bound molecule in tumor cells 6.1 Diagnostic Application Based on the…
Management of Prostate Cancer
Low-risk prostate cancer All of T1 or T2a, Gleason < 7, PSA < 10 Intermediate-risk prostate cancer Between low- and high-risk groups High-risk prostate cancer Any of T3 or T4, Gleason > 7, PSA > 20 In general…
